News >

Niraparib/Pembrolizumab Combo Active in Relapsed, Progressive TNBC

Published: Tuesday, Jun 05, 2018

Shaveta Vinayak, MD

Shaveta Vinayak, MD
Half of patients with metastatic triple-negative breast cancer (TNBC) achieved disease control when treated with the combination of a poly (ADP-ribose) polymerase (PARP) inhibitor and an anti–PD-1 agent, a preliminary prospective study showed.

The most frequent AEs (all grades, all 55 patients) were nausea (55%), fatigue (42%), anemia (31%), thrombocytopenia (24%), and constipation (20%). Grade ≥3 AEs consisted of anemia (15%), thrombocytopenia (13%), and fatigue (7%).
Vinayak S, Tolaney SM, Schwartzberg LS, et al. TOPACIO/Keynote-162: niraparib + pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial. J Clin Oncol. 2018;36(suppl; abstr 1011).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication